Basic HTML Version
© The Canadian Journal of Urology™; 18(Supplement 1); April 2011
28. Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill
BB, Hobbs.
J Clin Endocrin Metab
2004;89(5):2179-2184.
29. Roehrborn CG, Siami P, Barkin J, et al. The effects of dutasteride,
tamsulosin and combination therapy on lower urinary tract
symptoms in men with benign prostatic hyperplasia and
prostatic enlargement: 2-year results from the CombAT study.
J Urol
2008;179(2):616-621.
30. Lepor H, Williford WO, Barry MJ, Haakenson C, Jones K.
The impact of medical therapy on bother due to symptoms,
quality of life and global outcome, and factors predicting
response. VeteransAffairs Cooperative Studies Benign Prostatic
Hyperplasia Study Group.
J Urol
1998;160(4):1358-1367.
31. Roehrborn CG, Siami P, Barkin J. The effects of combination
therapy with dutasteride and tamsulosin on clinical outcomes
in men with symptomatic benign prostatic hyperplasia: 4-year
results from the CombAT study.
Eur Urol
2010;57(1):123-131.
32. Debruyne FM, Jardin A, Colloi D et al. Sustained-release
alfuzosin, finasteride and the combination of both in the
treatment of benign prostatic hyperplasia. Europeal ALFIN
Study Group.
Eur Urol
1998;34(3):169-175.
33. Siami P, Roehrborn CG, Barkin J et al. Combination therapy
with dutasteride and tamsulosin in men with moderate-to-
severe benign prostatic hyperplasia and prostate enlargement:
the CombAT (Combination of Avodart and Tamsulosin) trial
rationale and study design.
Contemp Clin Trials
2007;28(6):770-
779.
19
Benign prostatic hyperplasia and lower urinary tract symptoms: evidence and approaches for best casemanagement